Evaluation of periostin level for predicting severity and chronicity of childhood atopic dermatitis

Abstract

IntroductionPeriostin has some effects on the pathogenesis of atopic dermatitis (AD) via release of pro-inflammatory cytokines and chemokines from activated keratinocytes and it is related to chronicity of skin lesions.AimTo evaluate the relationship between plasma periostin levels and severity and chronicity of AD in children.Material and methodsThe study population consisted of 29 children with atopic dermatitis without concomitant allergic disease such as asthma or allergic rhinitis and 31 healthy controls. Data of demographic features, serum eosinophil, total IgE and skin prick test results were collected through the patient’s medical records. The severity of the disease was assessed by the SCORAD index. Serum periostin levels were measured with a human periostin ELISA kit.ResultsThe mean ages of the AD patients and the control group participants were 80.7 ±52.8 and 90.3 ±41.6 months, respectively. Mean plasma periostin levels were 63.0 ±19.0 ng/ml in AD patients, and 23.6 ±7.3 in healthy controls, and there was a statistically significant difference between the two groups (p = 0.001). Plasma periostin level did not vary according to total IgE or serum eosinophil count (p > 0.05). Age of onset and duration of symptoms also were not correlated with plasma periostin levels. Although there was a positive relationship between plasma periostin level and the SCORAD index of patients, it was not statistically significant (r = 0.19, p > 0.05).ConclusionsThis study showed that plasma periostin levels were increased in children with atopic dermatitis. Periostin may have a partial role in the pathogenesis of atopic dermatitis, but it is not associated with severity or chronicity in children with atopic dermatitis.

Indole-3-Carbinol Alleviates Allergic Skin inflammation via Periostin/Thymic Stromal Lymphopoietin Suppression in Atopic Dermatitis

“…Its onset stems from a multifaceted interplay of environmental and genetic factors [22], with immune-in ammatory complexities often heralding the development of asthma and other allergic conditions [23]. Periostin has recently emerged as a promising biomarker of type 2 in ammation in allergic diseases [24], notably induced by signature type 2 cytokines like IL-4 and IL-13 or exacerbating their effects, thereby propagating allergic skin in ammation [25]. Moreover, periostin assumes a critical role in AD pathogenesis by orchestrating the release of pro-in ammatory cytokines and chemokines, such as TSLP, IL-25, and IL-33, from activated keratinocytes [11].…”

Evaluation of the Diagnostic Significance of Some Biomarkers in Pruritic Dermatological Diseases: A Case-Control Study

“…10,13 Periostin has specific effects on AD pathogenesis involving the release of proinflammatory cytokines and chemokines from activated keratinocytes. 14,15 In a previous study involving in vitro organotypic culture systems, it was found that periostin promoted the survival and proliferation of keratinocytes and the production of directly induced thymic stromal lymphopoietin (TSLP). Based on these findings, the authors suggested that periostin aggravates AD patho-genesis through TSLP production from keratinocytes.…”

Serum Periostin as a Potential Biomarker in Pediatric Patients with Primary Hypertension

“…Sample size was estimated based on available literature on periostin with statistical power 0.8, p = 0.05, and effect size 0.55 should be ~50 [ 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 ]. Fifty pediatric patients with PH were recruited to this single-center cross-sectional study from patients hospitalized in a pediatric nephrology center between February 2018 and March 2019.…”